Xianqun Chu

Jining First People's Hospital

Papers

1

Total Citations

4

H-Index

1

About

Dr. Xianqun Chu is a leading clinical researcher in surgical oncology, with a primary focus on gastric cancer treatment and perioperative care. His most significant contributions center on optimizing recovery outcomes for patients undergoing laparoscopic or robotic radical gastrectomy, particularly those who have received neoadjuvant chemotherapy. Dr. Chu is the principal investigator of the landmark GISSG2023-01 Study, a multicenter randomized controlled trial that investigates the effect of perioperative probiotic supplements on short-term clinical outcomes. This work addresses a critical gap in managing the gut microbiome during aggressive cancer therapy, aiming to reduce postoperative complications and improve recovery. With his study protocol already garnering 4 citations shortly after publication, Dr. Chu’s research is gaining rapid recognition for its innovative approach to integrating nutritional microbiology with advanced surgical techniques. His work not only advances the evidence base for enhanced recovery after surgery (ERAS) protocols but also offers practical, translational strategies to improve the quality of life for patients with advanced gastric cancer. Dr. Chu’s dedication to rigorous clinical trial design positions him as an emerging authority in gastrointestinal surgical oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
4
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Effect of perioperative probiotic supplements on the short-term clinical outcomes of patients undergoing laparoscopic or robotic radical gastrectomy after neoadjuvant chemotherapy: Study protocol for a multicenter randomized controlled trial (GISSG2023 - 01 Study)
4 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 25
🏛 Institutions: Jining First People's Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago